window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 1, 2025

  • News
  • About Us
Contact Us

autoimmune disease

  • Artificial Intelligence,Biotech,Chronic diseases,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Single Cell analysis,Technology and platforms

    Immunai signs $85 million AstraZeneca deal to advance inflammatory bowel disease target

    Immunai has signed an agreement worth up to $85 million [...]

    October 16, 2025
  • European biotech,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development

    Enhanced Genomics extends Series A to $19m to advance autoimmune therapeutics pipeline

    Enhanced Genomics has secured an additional funding round, bringing its [...]

    September 22, 2025
  • Clinical Trials,Pharmaceuticals and therapeutics,Regulatory Affairs

    J&J halts Imaavy rheumatoid arthritis trial after no added benefit

    Johnson & Johnson has dropped plans to develop its recently [...]

    September 14, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Rare Diseases,Regulatory Affairs

    FDA grants fast track to Nektar’s rezpegaldesleukin for severe alopecia areata

    Nektar Therapeutics has received FDA Fast Track designation for its [...]

    July 29, 2025
  • Cell & Gene Therapy,Clinical Development,Clinical Trials,Oncology

    Novotech report explores how in-vivo CAR-T could transform cell therapy access and costs

    A new whitepaper from Novotech has outlined how in-vivo CAR-T [...]

    July 18, 2025
  • Biologics & Biosimilars,Precision medicine

    Enhanced Genomics appoints biotech veteran Dietrich Stephan as chair to drive next-gen target discovery

    Enhanced Genomics has appointed leading biotechnology entrepreneur Dietrich Stephan as [...]

    June 12, 2025
  • Cell & Gene Therapy,Drug Development,Technology and platforms

    Commit Biologics launches Scientific Advisory Board to accelerate BiCE platform development

    Commit Biologics has announced the formation of a Scientific Advisory [...]

    June 9, 2025
  • Clinical Trials,Drug Development,Patient Centricity,Regulatory Affairs

    NICE backs mirikizumab for treatment-resistant Crohn’s disease

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 30, 2025
  • Cell & Gene Therapy

    GeneFab and RegCell partner to advance autoimmune Treg therapy toward US trials

    May 7, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Thermo Fisher Scientific accelerates biologic therapeutics development with new CHO K-1 cell line
    Categories: Biologics & Biosimilars, CDMOs & Manufacturing, Cell & Gene Therapy
  • FairJourney Biologics appoints Werner Lanthaler as chief executive officer
    Categories: Biologics & Biosimilars, Biotech, Movers & Shakers
  • Digital therapeutic cuts schizophrenia’s negative symptoms in trial
    Categories: Clinical Trials, Digital Health, Mental health, Neurosciences
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top